Axsome Therapeutics, Inc.

A week after announcing results for solriamfetol in attention deficit hyperactivity disorder (ADHD) that left some analysts questioning its market differentiation, Axsome Therapeutics has released top

Axsome Therapeutics scored a win with the Phase III FOCUS trial of solriamfetol in attention deficient hyperactivity disorder (ADHD) among adults, which supports further development of the drug but ha

Fresh off its approval from the US Food and Drug Administration, Axsome Therapeutics’ migraine drug Symbravo (meloxicam and rizatriptan) stands to potentially strengthen its position in a crowded mark

The US Food and Drug Administration is starting to post information to key drug databases on its website again after most of its public communications were halted 21 January. The Center for Drug Evalu